Catalog Presentation: HDO Technology, which is expected to improve enzyme resistance in the bloodstream and reduce toxicity.
Our company handles "Hetero Double-Stranded Nucleic Acid (HDO)," which can selectively deliver active strands to disease sites by binding ligands to carrier strands, thereby expecting high therapeutic efficacy. HDO has a double-stranded structure, making it inherently stable. It avoids chemical modifications to the active strand, which can reduce toxicity. 【Features】 ■ Selectively delivers active strands to disease sites, achieving high therapeutic efficacy ■ Avoids chemical modifications and reduces toxicity ■ Provides a structurally stable material, improving enzyme resistance in the bloodstream ■ Low likelihood of unexpected therapeutic effects ■ Allows for free selection of the position and number of ligands binding to the carrier strand ■ The HDO technology is licensed to Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals (USA), Nippon Shokubai Co., Ltd., and Nippon Gene Material Co., Ltd. ■ The HDO technology is covered by multiple registered patents, ensuring safe use. ■ Collaborative research using HDO technology for drug discovery can also be conducted with our company. *For more details, please download the PDF or contact us.
Inquire About This Product
basic information
**Mechanism of Action of HDO** ■Step 1 → HDO taken up into the cell is cleaved by RNase H (enzyme), resulting in the carrier strand (RNA strand) being cut. ■Step 2 → The remaining active strand (DNA strand) after cleavage binds to the target mRNA. ■Step 3 → The active strand (DNA strand) binding to mRNA forms a DNA/RNA structure again, leading to the cleavage of the target mRNA by RNase H. ■Step 4 → The cleavage of mRNA suppresses mRNA expression, resulting in the manifestation of the drug's efficacy. *RNase H has the property of cleaving RNA in a double strand composed of DNA/RNA.* *For more details, please download the PDF or feel free to contact us.*
Price range
Delivery Time
Applications/Examples of results
Our company holds the following two seeds: - NASH therapeutic agent that regulates the expression of the IHH gene (early seed) - Tumor cell malignancy suppressor and melanoma therapeutic agent that regulates the expression of the ZIC5 gene (early seed)
catalog（2）
Download All Catalogs
Company information
Renac Therapeutics Co., Ltd. aims to create new nucleic acid drugs through a platform-based business model. Instead of a business model that derives profits by licensing out drugs developed through in-house research to pharmaceutical companies (the so-called pipeline model), we are developing a business model that collaborates with pharmaceutical companies from the drug discovery research stage and jointly develops drugs with them.
